Design of annulated pyrazoles as inhibitors of HIV-1 reverse transcriptase
Sweeney, Z.K., Harris, S.F., Arora, S.F., Javanbakht, H., Li, Y., Fretland, J., Davidson, J.P., Billedeau, J.R., Gleason, S.K., Hirschfeld, D., Kennedy-Smith, J.J., Mirzadegan, T., Roetz, R., Smith, M., Sperry, S., Suh, J.M., Wu, J., Tsing, S., Villasenor, A.G., Paul, A., Su, G., Heilek, G., Hang, J.Q., Zhou, A.S., Jernelius, J.A., Zhang, F.J., Klumpp, K.(2008) J Med Chem 51: 7449-7458
- PubMed: 19007201 
- DOI: https://doi.org/10.1021/jm800527x
- Primary Citation of Related Structures:  
3DYA, 3E01 - PubMed Abstract: 
Non-nucleoside reverse transcriptase inhibitors (NNRTIs) are recommended components of preferred combination antiretroviral therapies used for the treatment of HIV. These regimens are extremely effective in suppressing virus replication. Structure-based optimization of diaryl ether inhibitors led to the discovery of a new series of pyrazolo[3,4-c]pyridazine NNRTIs that bind the reverse transcriptase enzyme of human immunodeficiency virus-1 (HIV-RT) in an expanded volume relative to most other inhibitors in this class ...